[Intraurethral injections of Zuidex: evaluation of the morbidity of the technique in the treatment of female urinary incontinence].
OBJECTIVE
To evaluate the feasibility and morbidity of intraurethral injections of dextranomer/hyaluronic acid (Zuidex), performed under local anaesthesia as an outpatient procedure in the treatment of female urinary incontinence.


METHODS
Twenty one patients with a mean age of 67 years (range: 29-93 years) presenting urinary incontinence related to sphincter incompetence were treated by intraurethral injection of Zuidex. Injections were performed with the Implacer system provided with the product under local anaesthesia.


RESULTS
For nine of these patients (43%), a second injection after 6 weeks was performed due to an insufficient result on incontinence. A total of 30 injections were therefore performed. No significant problem was observed during the injections. Three injections (10%) were difficult because of a short urethra. In 7 cases (23%), the patient reported pain during the injection. In 3 cases (10%), macroscopic haematuria was observed after treatment and another 4 cases (13%) developed lower urinary tract infection. Six patients (20%) developed transient acute urinary retention with resumption of micturition after 24 to 48 hours.


CONCLUSIONS
Intraurethral injection of Zuidex has the advantage of being minimally invasive and can be performed under local anaesthesia, as an outpatient procedure, with good safety and a low complication rate. Resumption of spontaneous voiding must be monitored in view of the risk of urinary retention. The long-term results have not yet been evaluated.
Ferchaud
Jérôme
J
Service d'Urologie, Hôpital Tenon, Paris, France. jferchaud@9online.fr
Girard
Frédéric
F
Ciofu
Calin
C
Peyrat
Laurence
L
Haab
François
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000779:Anesthetics, Local / Q000008:administration & dosage; D001672:Biocompatible Materials / Q000627:therapeutic use*; D003911:Dextrans / Q000627:therapeutic use*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D007267:Injections; D008012:Lidocaine / Q000008:administration & dosage; D008875:Middle Aged; D019736:Prostheses and Implants; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000628:therapy*
D000779:Anesthetics, Local; D001672:Biocompatible Materials; D003911:Dextrans; C487487:dextranomer-hyaluronic acid copolymer; D006820:Hyaluronic Acid; D008012:Lidocaine